Gilead Teams Up with PEPFAR to Provide Biannual Lenacapavir for HIV Prevention to Nearly Two Million Individuals in Mainly Low- and Lower-Middle-Income Nations | Intellectia.AI
Gilead Teams Up with PEPFAR to Provide Biannual Lenacapavir for HIV Prevention to Nearly Two Million Individuals in Mainly Low- and Lower-Middle-Income Nations
Written by Emily J. Thompson, Senior Investment Analyst
Partnership for HIV Prevention: Gilead Sciences has partnered with the U.S. State Department and PEPFAR to deliver lenacapavir, an injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in resource-limited countries, aiming to support up to two million people over three years.
Access Strategy and Regulatory Approvals: Gilead is pursuing accelerated regulatory pathways for lenacapavir in high-incidence countries, including securing royalty-free agreements with generic manufacturers to ensure affordable access and meet demand, while also providing the medication at no profit until generics are available.
GILD
$119.78+Infinity%1D
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 135.00 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 135.00 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 120.400
Low
105.00
Averages
135.00
High
150.00
Current: 120.400
Low
105.00
Averages
135.00
High
150.00
Morgan Stanley
Overweight
maintain
$147 -> $151
2025-12-12
New
Reason
Morgan Stanley
Price Target
$147 -> $151
2025-12-12
New
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Gilead to $151 from $147 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
HSBC
Hold
maintain
$110 -> $133
2025-12-10
Reason
HSBC
Price Target
$110 -> $133
2025-12-10
maintain
Hold
Reason
HSBC raised the firm's price target on Gilead to $133 from $110 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
Needham
Needham
Buy
maintain
$14
2025-12-08
Reason
Needham
Needham
Price Target
$14
2025-12-08
maintain
Buy
Reason
Needham reiterated a Buy rating and $14 price target on Vir Biotechnology (VIR), saying that Mirum's (MIRM) announced takeover of Bluejay Therapeutics is a positive readthrough to Vir. The firm believes this given its view that Vir's elebsiran/tobevibart profile is better than Bluejay and Gilead (GILD); the deal signals very high interest in the Hepatitis Delta Virus commercial opportunity, and; the deal size is quite favorable for a potentially third-to-market asset. The firm anticipates Vir to trade up Monday on the news and believes the company's HDV program is underappreciated by investors and not adequately reflected in the stock at current levels.
Truist
Gregory Renza
Buy
downgrade
$145 -> $140
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$145 -> $140
2025-11-24
downgrade
Buy
Reason
Truist analyst Gregory Renza assumed coverage of Gilead with a Buy rating with a price target of $140, down from $145. The firm is positive on the continued strength for the company's HIV franchise, supported by Biktarvy's patent settlement and positive momentum across next-generation programs,most notably Yeztugo's PrEP launch and Bic/Len's positive phase 3 readout, pointing to a healthy outlook into the next-decade, the analyst tells investors in a research note. Truist adds that it also views the oncology franchise as a key growth pillar led by Trodelvy and anito-cel, further noting that Livdelzi's launch in PBC - Primary Biliary Cholangitis - is off to a strong start.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
